Semaglutida – uma alternativa no tratamento da obesidade?
Article Sidebar
Main Article Content
Abstract
Objetivo: Analisar as vantagens de desvantagens da Semaglutida para o tratamento da obesidade. Métodos: Análise de diferentes artigos científicos. O presente artigo estabeleceu como critérios de inclusão, estar em uma das plataformas pré-selecionadas (SciELO, PubMED, PebMED, Scopus, MedLine), serem artigos dos anos 2013 a 2023 e estabeleceu como critérios de exclusão, pesquisas incompletas, fora da temática pesquisada e sem métodos e resultados explícitos e fora do período selecionado.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Statement - Policy Proposal for Open Access Journals
Authors who publish in the Brazilian Journal of Natural Sciences (BJNS) agree to the following terms: 1 - Authors retain the copyright and grant the journal the right to first publication, with the work simultaneously licensed under the Creative Commons Attribution License allowing sharing of the work with recognition of the authorship of the work and initial publication in this journal. 2 - Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. 3 - Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and citation of published work. This is an open access article under the CC-BY license
(http://creativecommons.org/licenses/by/4.0)
References
Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: An EASO
position statement on a diagnostic term with clinical and scientific
implications. Obes Facts. 2019;12(2):131–6. PMID: 30844811. PMCID:
PMC6547280.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9: 88. PMID: 19320986. PMCID: PMC2667420. https://doi.org/10.1186/1471-2458-9-88
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9: 88. PMID: 19320986. PMCID: PMC2667420. https://doi.org/10.1186/1471-2458-9-88.
Van Bloemendaal L, ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS. J Endocrinol. 2014;221(1):T1-16. PMID: 24323912. https://doi.org/10.1530/JOE-13-0414.
Harvard T.H. Chan School of Public Health. Health Risks [Internet]. Obesity Prevention Source. 2016. Available from: https://www.hsph.harvard.edu/obesity-prevention-source/obesity-consequences/health-effects
World Health Organisation. Obesity and Overweight [Internet]. World Health Organization. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007 Oct;87(4):1409–39.
Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, et al. Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism. 2011 Aug 8;13:89–94.
Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57
O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso | Revista Artigos. Com. acervomaiscombr [Internet]. 2021 Jun 29; Available from: https://acervomais.com.br/index.php/artigos/article/view/7498/4988
Nauck MA, Petrie JR, Sesti G, et al; Estudo 1821 Pesquisadores. Um estudo de fase 2, randomizado, de determinação de dose do novo análogo humano GLP-1 uma vez por semana, semaglutide, comparado com placebo e liraglutide a céu aberto em pacientes com diabetes tipo 2. Cuidados com o Diabetes. 2016;39:231–241.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016 Nov 10;375(19):1834–44. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
joejigsaw. On-Demand Education [Internet]. The Obesity Society. Available from: https://www.obesity.org/meetings-education/on-demand-education/?gclid=CjwKCAjwrJ-hBhB7EiwAuyBVXeJvYLO0sB_nBZxuvjFO1R3bl7UWgdM_J2Qya9o-qF5Y5LsvhbMnkxoC-O8QAvD_BwE
CDC (21 March 2022). "Causes and Consequences of Childhood Obesity". Centers for Disease Control and Prevention. Retrieved 18 August 2022.